6:30 AM-7:45 AM Complimentary Continental Breakfast Provided
6:30 AM-6:30 PM Exhibits
7:00 AM-7:45 AM

Breakout Session: Immunology 101: The Basics


Marka R. Crittenden, MD, PhD
Earle A. Chiles Research Institute, Providence Cancer Center


Panel Question and Answer

7:45 AM-9:30 AM

Welcome and General Session 1: What Are the Best Immunogenic Targets for Cancer Immunotherapy?


Brad Nelson, PhD—Chair
BC Cancer Agency


Mary L. (Nora) Disis, MD
University of Washington



Brad Nelson, PhD
BC Cancer Agency

Session Overview


Carl G. Figdor, PhD
Radboud Institute for Molecular Life Sciences

Vaccines Targeting Mutations


Kunle Odunsi, MD, PhD
Roswell Park Cancer Institute

Can Immunity Be Generated to “Self” Cancer-Associated Antigens?


Olivera J. Finn, PhD
University of Pittsburgh
Shared Antigens as Vaccines for Cancer Prevention 



Panel Question and Answer

9:30 AM-10:00 AM Break
10:00 AM-11:30 AM

General Session 2: Driving T-Cell Therapies Forward to the Clinic—For Everyone


Stephen Gottschalk, MD—Chair
Baylor College of Medicine

CAR T Cells for Solid Tumors: What Are the Challenges?


Cameron J. Turtle, MBBS, PhD
Fred Hutchinson Cancer Research Center

CAR T Cells for B-Cell Malignancies


Prasad S. Adusumilli, MD
Memorial Sloan Kettering Cancer Center

CAR T Cells for Solid Tumors in Combination with Immune Checkpoint Blockade


Ann M. Leen, PhD
Baylor College of Medicine

Multi-tumor-Associated Antigen-Specific T Cells for Therapy


Christopher A. Klebanoff, MD
Center for Cell Engineering and Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center

Neoantigen-Specific T-Cell Receptors: From Bench to Bedside


Panel Question and Answer

11:45 AM-1:00 PM

Networking Roundtables: Where Does Immunotherapy Fit in Your Practice?


Expert faculty willl lead small-group discussions on hematologic malignancies, head and neck cancers, sarcoma, colorectal cancer, brain cancer, and melanoma.


For a list of the faculty participants, please visit Networking Opportunities.

11:30 AM-1:00 PM

Poster Session A

With Complimentary Boxed Lunch

1:00 PM-2:15 PM

Oral Abstract Session A


Jeffrey Schlom, PhD - Co-Chair

National Cancer Institute Center for Cancer Research


John Nemunaitis, MD - Co-Chair

Mary Crowley Cancer Research Centers


Abstract 138: The impact of checkpoint blockade prior to adoptive cell therapy using tumor-infiltrating lymphocytes for metastatic melanoma: An update from MD Anderson Cancer Center.

First author: Marie-Andree Forget


Discussion: Claire Friedman, MD

Memorial Sloan Kettering Cancer Center


Abstract 139: Plinabulin as a novel small molecule clinical stage immuno-oncology agent for NSCLC.

First author: Ramon Mohanlal


Abstract 140: Correlation between strength of T-cell response against HPV16 and survival after vaccination with HPV16 long peptides in combination with chemotherapy for late-stage cervical cancer.

First author: Cornelis Melief


Discussion: Heather McArthur, MD, MPH

Cedars-Sinai Medical Center


Panel Question and Answer

2:15 PM-3:00 PM

Keynote Lecture


Ronald N. Germain, MD, PhD
National Institutes of Health

Assessing Anticancer Immune Responses Using Advanced Microscopy Methods

3:00 PM-3:30 PM Break
3:30 PM-5:00 PM

General Session 3: Activating the Immune System—New Clinical Approaches


Ezra E.W. Cohen, MD—Chair
University of California, San Diego


Brendan D. Curti, MD
Earle A. Chiles Research Institute, Providence Cancer Center

OX40 Monoclonal Antibodies in the Clinic


Elizabeth A. Repasky, PhD
Roswell Park Cancer Institute

Thermal Costimulation: Heating Up the Immune System


Omid Hamid, MD
The Angeles Clinic and Research Institute

Optimizing Immunity in Melanoma via T-Cell Activation


Abstract 77: Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and -010
First Author: Matthew Hellman


Abstract 78: Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12)
First Author: Alain Algazi


Panel Question and Answer

5:00 PM-5:30 PM

Evening Highlights: How Will Today’s Presentations Impact Clinical Practice?


Ann W. Silk, MD
Rutgers Cancer Institute of New Jersey


Panel Question and Answer

5:30 PM-6:30 PM

Poster Session A (Continued) and Networking Reception

With Complimentary Wine and Cheese

5:45 PM-6:30 PM

Poster Walks


Julie Djeu, PhD

H. Lee Moffitt Cancer Center & Research Institute


Kavita Dhodapkar, MD

Yale University